New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
10:03 EDTZFGN, WHLR, TRI, MRKT, JMP, FDS, EQIX, DANG, CONE, CRMD, CECEOn The Fly: Analyst Downgrade Summary
Today's noteworthy initiations include: CECO Environmental (CECE) initiated with a Buy at Canaccord... CorMedix (CRMD) initiated with a Buy at Roth Capital... CyrusOne (CONE) initiated with an Equal Weight at Barclays... Dangdang (DANG) initiated with a Buy at Citigroup... Equinix (EQIX) initiated with an Equal Weight at Barclays... FactSet (FDS) initiated with a Buy at Jefferies... JMP Group (JMP) initiated with an Outperform at Barrington... Markit (MRKT) initiated with a Hold at Jefferies... Thomson Reuters (TRI) initiated with a Hold at Jefferies... Wheeler REIT (WHLR) initiated with a Buy at Maxim... Zafgen (ZFGN) initiated with an Outperform at Leerink.
News For CECE;CRMD;CONE;DANG;EQIX;FDS;JMP;MRKT;TRI;WHLR;ZFGN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
16:58 EDTJMPJMP Group increases quarterly dividend 16% to 7c
JMP Group announced that its board has voted to raise the companyís cash dividend to 7c per share for Q3, an increase of more than 16% from 6c per share for the prior quarter. The dividend will be paid on November 28 to common stockholders of record as of November 14.
07:09 EDTTRIThomson Reuters backs FY14 revenue to be comparable to FY13, consensus $12.67B
Subscribe for More Information
07:08 EDTTRIThomson Reuters reports Q3 adjusted EPS 45c, consensus 45c
Subscribe for More Information
October 29, 2014
16:37 EDTEQIXEquinix raises FY14 revenue guidance to $2.43B-$2.44B, consensus $2.43B
Subscribe for More Information
16:34 EDTEQIXEquinix sees Q4 revenue $627M-$631M, consensus $642.02M
For Q4, the company expects revenues to range between $627M-$631M, which includes a negative foreign currency impact of approximately $11M compared to the rates used from the company's prior guidance. Cash gross margins are expected to approximate 68%-69%. Cash selling, general and administrative expenses are expected to approximate $139M. Adjusted EBITDA is expected to range between $291M-$295M, which includes $6M in professional fees and costs primarily related to the REIT conversion and a negative foreign currency impact of approximately $5M compared to the rates used from the company's prior guidance. Capital expenditures are expected to range between $210M-$230M, comprised of approximately $35M of recurring capital expenditures and $175M-$195M of expansion capital expenditures.
16:31 EDTEQIXEquinix reports Q3 adjusted EPS 79c, consensus 89c
Reports Q3 revenue $620.4M, consensus $615.85M.
09:48 EDTJMPJMP Group management to meet with Barrington
Meeting to be held in New York on November 5 hosted by Barrington.
09:44 EDTJMPJMP Group management to meet with Barrington
Subscribe for More Information
07:44 EDTDANGDangdang coverage assumed with an Equal Weight at Morgan Stanley
Price target lowered to $12 from $15.50.
October 28, 2014
07:22 EDTTRINYSSA to hold a conference
Subscribe for More Information
October 27, 2014
08:54 EDTCRMDCorMedix receives approval from FDA to initiate Neutrolin clinical trial
CorMedix announced that the FDA has reviewed its Investigational New Drug application, or IND, for Neutrolin which was submitted September 24, and determined that the IND is not subject to a clinical hold, and that a pivotal clinical study can be initiated in the United States. CorMedix is a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiac, renal and infectious diseases. The IND includes a pivotal Phase 3 protocol for Neutrolin in hemodialysis patients with a central venous catheter. The Phase 3 clinical trial will be a multi-center, randomized, controlled study conducted in the U.S. and Europe. Dr. Michael Allon, Professor, Department of Medicine, Division of Nephrology, University of Alabama, Birmingham will be the Study Chair of the Neutrolin Phase 3 program. CorMedix is currently developing an additional Phase 3 protocol to support the use of Neutrolin to prevent catheter related infections for oncology patients receiving total parenteral nutrition.
October 24, 2014
10:03 EDTEQIXOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:22 EDTEQIXEquinix downgraded to Market Perform at Cowen
Subscribe for More Information
08:02 EDTJMPJMP Group reports Q3 operating EPS 15, two estimates 14c
Subscribe for More Information
06:07 EDTEQIXEquinix downgraded to Market Perform from Outperform at Cowen
Subscribe for More Information
October 23, 2014
08:40 EDTWHLRWheeler REIT completes transition to internally-managed REIT
Subscribe for More Information
October 20, 2014
08:10 EDTEQIXHurricane Electric extends global IPv4 and IPv6 network in Asia and Europe
Subscribe for More Information
07:10 EDTTRIAmerican Society of Human Genetics to hold annual meeting
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use